1. USFood and Drug Administration. Guidance for industry: exposure‐response relationships—study design data analysis and regulatory applications.https://www.fda.gov/media/71277/download. Published 2003. Accessed May 7 2021.
2. US Food and Drug Administration. Guidance for industry: E11(R1) addendum: clinical investigation of medicinal products in the pediatric population.https://www.fda.gov/media/101398/download. Published 2018. Accessed May 7 2021.
3. Applying the non‐inferiority paradigm to assess exposure‐response similarity and dose between pediatric and adult patients;Zhang Q;J Clin Pharmacol,2021
4. US Food and Drug Administration: Guidance for industry: general clinical pharmacology considerations for pediatric studies for drugs and biological products.https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-pediatric-studies-drugs-and-biological-products. Accessed on January 27 2021.
5. Dosing recommendations for pediatric patients with renal impairment;Al‐Khouja A;J Clin Pharmacol,2020